TDC
ATRA icon

Thompson Davis & Co’s Atara Biotherapeutics ATRA Stock Holding History

Thompson Davis & Co’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$5K Hold
5
– – 0.01% 561
2018
Q2 		$5K Hold
5
– – 0.01% 510
2018
Q1 		$5K Hold
5
– – 0.01% 473
2017
Q4 		$2K Buy
+5
New +$1.85K ﹤0.01% 597

Other funds holding ATRA

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Eagle Asset Management
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Thompson Davis & Co's ATRA Position: Q3 2018 in Review

Thompson Davis & Co held its Atara Biotherapeutics (ATRA) position steady in Q3 2018 at 5 shares worth $5K. The position accounts for 0.01% of the portfolio, ranked #561.

Thompson Davis & Co first reported a position in ATRA in Q4 2017 and has held it in 4 quarters since. 115 funds tracked by Wall St. Rank hold ATRA as of Q3 2018.

  • Thompson Davis & Co held 5 shares of Atara Biotherapeutics worth $5K as of Q3 2018.
  • Thompson Davis & Co left its Atara Biotherapeutics share count unchanged in Q3 2018.
  • Atara Biotherapeutics made up 0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #561 holding.
  • Thompson Davis & Co first reported a position in Atara Biotherapeutics in Q4 2017 and has held it in 4 quarters since.
  • 115 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.